Sajid Javid: Valneva COVID vaccine would not have been approved by MHRA
September 15, 2021Manufacturing and Production, Medical Communications, Research and Development
On Monday the UK cancelled a deal with French vaccine maker Valneva worth up to €1.4 billion, and Health Secretary …
NHS in Scotland makes rheumatoid arthritis drug available
September 14, 2021Manufacturing and Production Galapagos UK, NHS, Scotland, filgotinib, rheumatoid arthritis
The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for eligible patients with severe active …
Israeli survey finds 1 in 10 children have long COVID
September 14, 2021Medical Communications, Research and Development
An Israeli Health Ministry survey has found that one in ten children have lingering COVID-19 symptoms after contracting and recovering …
J&J publish promising Ebola vaccine data
September 14, 2021Research and Development
Johnson & Johnson have released promising data regarding their Ebola vaccine regimen, as it demonstrates antibody immune responses in adults …
NHS launches new blood test to detect over 50 types of cancer early
September 13, 2021Sales and Marketing
A world-first trial of a new cancer test began today as the NHS launched its Galleri trial, which seeks to …
BioNTech seek approval for COVID-19 vaccine in children aged 5-11
September 13, 2021Sales and Marketing COVID-19, FDA, Vaccine, children
Children between 5 and 11 years old are to be targeted by BioNTech as the company seeks approval for younger …
Valneva COVID-19 vaccine deal pulled by UK government
September 13, 2021Research and Development, Sales and Marketing Boris Johnson, Scotland, UK government, Vaccine, Valneva, booster, covid19
Boris Johnson and the UK government have terminated its deal with specialist vaccine company Valneva after it was alleged the …
NICE recommends Pfizer’s Xeljanz for juvenile idiopathic arthritis
September 10, 2021Medical Communications
NICE has published final draft guidance recommending the use of Pfizer’s Xeljanz (tofacitinib) as an option for treating active polyarticular …
Pfizer and AstraZeneca approved as booster COVID vaccines
September 10, 2021Medical Communications
The MHRA has approved the use of Pfizer and AstraZeneca’s COVID-19 vaccines for the planned booster programme this winter. However, …
NHS lung cancer patients to receive Amgen’s tumour-stopping drug
September 10, 2021Medical Communications, Research and Development
NHS patients will be the first in Europe to receive a new drug that can prevent lung cancer tumour growth, …
FDA grants Fast Track Designation for Vor Biopharma’s AML drug
September 10, 2021Medical Communications, Research and Development
Vor Biopharma has announced that the FDA has granted their acute myeloid leukemia (AML) engineered hematopoietic stem cell therapy (eHSC), …
Hope for non-cystic fibrosis bronchiectasis patients following positive Phase III results
September 9, 2021Pharmaceutical company Zambon has announced positive results from the Phase III PROMIS-I study, which examined the use of colistimethate sodium …
AstraZeneca’s asthma drug reveals success in Phase III trials
September 9, 2021Avillion have announced the success of the MANDALA and DENALI Phase III trials of AstraZeneca’s PT027 (albuterol/budesonide), which revealed the …
Novavax begins clinical trial for combined influenza and COVID vaccine
September 9, 2021US vaccine developer Novavax has announced the initiation of an early stage clinical trial investigating its combined influenza and COVID-19 …
Compulsory COVID and flu jabs being considered for England health staff
September 9, 2021Plans to make COVID-19 and flu vaccinations compulsory for frontline NHS staff in England are currently being discussed by the …
Rare nerve disorder listed as possible side effect of AZ’s COVID vaccine in EU
September 9, 2021An extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), has been listed by EU regulators as a possible side effect from …
Trials of former Theranos CEO Elizabeth Holmes are underway
September 8, 2021Medical Communications, Research and Development
The highly anticipated trials of Elizabeth Holmes, founder and former CEO of the now-defunct Theranos, have commenced. Prosecutors are to …
J&J’s prostate cancer drug recommended by NICE
September 8, 2021Research and Development
J&J have announced NICE are recommending apalutamide for treating prostate cancer following new draft guidance by the body. This is …
Amneal’s IPX-203 shows promising results for motor fluctuations in Parkinson’s disease
September 8, 2021Research and Development
Amneal Pharmaceuticals has recently announced that its product IPX-203 (carbidopa + levodopa, (CD/LD)) achieved key primary and secondary endpoints in …
COVID booster vaccines to get green light in “next few days”, according to health secretary
September 8, 2021Research and Development
Coronavirus booster jabs are expected to be approved in “the next few days”, the UK Health Secretary, Sajid David, has …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
